63 results
8-K
EX-99.1
vj87r7
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
8-K
EX-99.2
qapvozits4w
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
exo93d99
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
81wwsh
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
424B5
x7obuez
15 Jun 23
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
0yto0mpt89
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
lyc0ownq u62l9e
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am